Clinical trials: Phase 1: Advanced or Refractory Solid Tumours
- Condition Phase 1: Advanced or Refractory Solid Tumours
- Funder type Industry (pharma, biotech, devices)
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Neoplasms
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
This Phase 1 study will be conducted in an open-label, non-randomized, dose-escalation design in subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy.
- Trial name
- NCT01585870
- Testing
- Sorafenib (Nexavar, BAY43-9006), Eribulin
- Where
- 4 sites in France, Germany
- Volunteers
- 40 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel.
- Trial name
- NCT03595059
- Testing
- ABBV-155, Paclitaxel, Docetaxel
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Solid Tumors, Tenosynovial Giant Cell Tumor
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory…
- Conditions
- Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
- Trial name
- NCT02673736
- Testing
- PLX73086
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Plexxikon
Advanced Solid Tumors
Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)
A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.
- Trial name
- NCT00359671
- Testing
- MK6592, comparator: docetaxel
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Advanced Solid Tumor, Lymphoma
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or…
- Conditions
- Advanced Solid Tumor, Lymphoma, NSCLC, HCC
- Trial name
- NCT05341557
- Testing
- BPI-371153
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
HER2 or EGFR Expressing Advanced Solid Malignancies
MAD Refractory: Solid Tumor QD w/o Break
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
- Trial name
- NCT00207012
- Testing
- BMS-599626
- Where
- 2 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
A dose escalation study to establish the safety profile and characterize the pharmacokinetic profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to standard therapy or for which no standard…
- Trial name
- NCT01346358
- Testing
- IMC-CS4
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Advanced Unresectable Solid Tumors
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors…
- Trial name
- NCT02508441
- Testing
- Andes-1537 for Injection
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andes Biotechnologies
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1…
- Trial name
- NCT05431270
- Testing
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Phanes Therapeutics
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
Cancer
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Assess the safety and tolerance of a weekly MEDI522 regimen in patients with irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.
- Trial name
- NCT00284817
- Testing
- MEDI-522
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- MedImmune LLC
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.
- Trial name
- NCT01014936
- Testing
- MSC2156119J
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- EMD Serono